DEA Boosts Psychedelics Production For Research, Cannabis Quotas Hold Steady Ahead Of Rescheduling

The Drug Enforcement Administration (DEA) has unveiled new production quotas for Schedule I and II controlled substances, with a notable emphasis on boosting the supply of certain psychedelics for research purposes. As Marijuana Moment reported, among the substances marked for increased production are psilocybin, psilocyn and ibogaine, reflecting growing scientific ...

Continue Reading →

Oxa-Iboga alkaloids lack cardiac risk and disrupt opioid use in animal models

Ethical considerations

All experimental procedures involving animals were approved by the Columbia University, Memorial Sloan Kettering Cancer Center, Rutgers University or High Point University Institutional Animal Care and Use Committee (IACUC) and adhered to principles described in the National Institutes of Health Guide for the Care and Use of Laboratory Animals and abide by the ARRIVE guidelines.

All human hearts used for the present study were not suitable for transplantation and originated ...

Continue Reading →

3 Natural Substances Used as Replacements in Harm Reduction Therapies

Harm reduction strategies are designed to minimize the adverse effects of substance use rather than requiring abstinence. This concept often includes the use of natural substances as alternatives to more harmful or addictive drugs. Several substances are currently being explored for their therapeutic potential in reducing dependence on opioids, alcohol, and other addictive substances. The focus here is on three such natural substances: kratom, cannabidiol (CBD), and ibogaine. These compounds are being studied ...

Continue Reading →
Page 71 of 123 «...4050606970717273...»
UA-77446339-1